Navigation Links
Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
Date:9/17/2013

San Jose, California (PRWEB) September 17, 2013

Follow us on LinkedIn – In the coming months, GIA will complete an extensive secondary and primary research program involving some of the industry’s leading players and experts. The study will examine key drivers and trends impacting the market such as high prevalence of cancer worldwide; unmet medical needs in cancer treatment and diagnosis; strong investments in R&D designed to unlock the untapped potential of circulating cancer biomarkers; and supportive regulatory and reimbursement policies especially in developed countries.

Defined as cells separated from the tumor and circulating in the blood, circulating tumor cells are a primary cause for promoting metastasis. Identification of blood circulating tumor cells is therefore gaining in importance as a diagnostic tool. With the growing body of evidence supporting the view that circulating tumor cells (CTCs) can help predict outcome of cancerous tumors in patients, there is heightened interest in utilizing CTCs in improving prognosis and optimizing treatment choices by accurately predicting response to therapies. Circulating biomarker research is therefore gaining in importance. Circulating, cell-free microRNAs (miRNAs) will emerge as a promising new class of cancer biomarkers with valuable benefits in clinical practice. Molecular characterization of CTCs will aid in limiting metastasis in early stages thus improving the chances of survival. Ongoing technology advances are facilitating development of newer methods for detecting and removing CTCs that cause metastasis from blood. Growing popularity and adoption of personalized cancer medicine will additionally spur R&D efforts in developing tumor-specific biomarkers. The coming years will witness commercial opportunities for CTCs in the area of therapeutic selection and patient monitoring.

Fuelled by the need for more effective treatment options and growing focus of the medical community to develop drugs and therapies that target tumor roots, research in the field of Cancer Stem Cells (CSCs) is attracting increased investments. Stem cells also known as progenitor cells, represent cells that are capable of regenerating malignant tumor cells and thus are responsible for the spread of cancer. As a key cause for tumor recurrence, metastasis, and resistance, cancer stem cells are therefore an important theme for R&D, especially as a drug target. The coming years are forecast to witness the development of novel drugs that target cancer stem cells (CSCs).

In addition to technical growth drivers, key market forces fuelling growth include rising awareness about cancer among the patient base, growing disposable incomes and greater healthcare per capita spends especially in developing countries, establishment of latest healthcare facilities and improvement in quality of care offered, and supportive legislations that encourage R&D investments among big pharma companies by mitigating R&D risk exposure in this space.

The study estimates the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) to be a multi-million dollar market, while more precise market-size and growth projections will be made available during the 2nd stage of report preparation, and data analysis.

The research and analyses will be released shortly in the form of a comprehensive research report. The report by design, will attempt to provide exhaustive analysis, data, trends, market share, market size, statistics, forecasts and competitive intelligence. The report is modeled to offer precise and unbiased, actionable market insights including in-depth segmentation of market sub-sectors, demand estimates and projections and analysis of trends in each of the sectors, identification of leading players, and the competitive structure, among others.

Developed for Oncology Drug Developers and Manufacturers, Cancer Diagnostics Companies, Strategic Planners, Business Development Executives, Management Consultants, Investment Bankers, Consulting Firms, Marketing & Sales Executives, C-Level Decision Makers, Market Strategists and Technology Domain Experts, the report helps identify the biggest opportunities in this space and offers accurate latent demand forecasting that empowers quantitative decision making among existing market players and new entrants.

For more details about how you can participate, please click here

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/cancer_stem_cells/circulating_tumor_cells/prweb11130687.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):